
"I am glad that taking part in a trial might help others on their own cancer journey.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a drug called nintedanib after chemotherapy for pleural mesothelioma.
Mesothelioma is a type of cancer that can develop in the lining that covers the outer surface of the lungs. This is called pleural mesothelioma.
The usual treatment for pleural mesothelioma is chemotherapy. After chemotherapy you don’t have further treatment unless your cancer starts to grow again. Your doctor monitors your cancer to check this.
Researchers are looking for ways to improve treatment. They think that a drug called nintedanib might delay or stop the cancer coming back. But they aren’t sure so want to find out more.
Nintedanib is a type of targeted drug called a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
In this trial some people have nintedanib. And some have a dummy drug ().
The main aims of the trial are to:
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply.
You:
Who can’t take part
You cannot join this trial if any of these apply.
Cancer related
You:
Medical conditions
You:
Other
You:
This a phase 2 trial. The researchers need 114 people to join.
It is a randomised trial. You are put into 1 of 2 groups by a computer. Neither you nor your doctor can choose which group you are in. And neither you nor your doctor will know which group you are in. This is called a double blind trial.
You have 1 of the following:
You have treatment as long as it is working and side effects aren’t too bad. You stop treatment if it isn’t working. Your doctor will talk to you about other treatment options.
Samples for research
The researchers will ask for samples of your cancer (a ) that doctors took when you were first diagnosed. They also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
They plan to look at:
Activities of daily living questionnaire
You fill out a questionnaire at set times during the trial and after finishing treatment. The questionnaire is for older people to find out how they cope with activities of daily living. For example it asks about your ability to use the telephone, shop and prepare meals.
You see a doctor and have some tests before you start treatment. The tests include
Every 4 weeks you have:
You have a CT scan or MRI scan every 2 months.
When you finish treatment you see the trial team every 3 months. Or they phone you to see how you are getting on.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
The most common side effects of nintedanib are:
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Sanjay Popat
European Organisation for Research and Treatment of Cancer (EORTC)
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”